Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
8
×
boston top stories
indiana blog main
8
×
indiana top stories
life sciences
national blog main
national top stories
novartis
8
×
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
eli lilly
medicare
merck
pfizer
abbvie
alzheimer's disease
amgen
deals
diagnostics
drug prices
president trump
What
drug
8
×
bio
roundup
approval
new
acquisitions
biggest
ceo
companies
fda
latest
medicines
patients
pharmaceutical
plan
price
prices
today
address
advantages
albert
alzheimer’s
amgen
approves
away
bar
biogen’s
biopharmaceutical
blueprint
bourla
bringing
brings
build
buy
cancer
candidates
carries
ceos
certain
class
Language
unset
unknown
Current search:
drug
×
biotech
×
novartis
×
" indiana blog main "
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines